Kornimate/medical-research-clean huggingface dataset:
map healthcare provision outside the nhs

Conditions: Healthcare Providers

Summary: * to collect data to show which sites outside of the nhs are currently being signposted to patients by healthcare multidisciplinary professionals * to collect data about these sites, from patients who have been referred or signposted to sites outside of the nhs from a healthcare multidisciplinary professional * to develop a database of potential healthcare sites outside the nhs that could become involved in nihr healthcare

this is a small-scale pilot project to test out the research design and methodology. this pilot project will take a small-scale approach to mapping non-nhs providers that are currently (a) being recommended and signposted by healthcare professionals and (b) have been experienced by patients. a sample of around 100 participants who are (a) currently employed in a range of healthcare provision settings or who (b) have experienced healthcare provision outside the nhs and who (i) have regular access to internet access in order to access a blog; and (ii) have sufficient english language skills to read and understand questions posted on the blog, will be recruited. participants will be asked to provide information via a blog about which non-nhs healthcare provision they would signpost or recommend. there will be opportunities both to record data and to communicate and form discussions with other participants on the blog. this data will be coded and collated onto a database and analysed thematically.

Eligibility criteria:
inclusion criteria: * currently employed in a healthcare setting in a role that involves direct contact with patients for at least one day per week or * have been a patient accessing non-nhs healthcare provision within the last two years. * must have self-reported, sufficient english language ability to read the blog * have regular personal access to the internet. exclusion criteria: * not currently employed in a healthcare setting in a role that involves direct contact with patients for at least one day per week or * not have been a patient accessing non-nhs healthcare provision within the last two years. * not have self-reported, sufficient english language ability to read the blog * not have regular personal access to the internet.
dorefa (retinal detachment: function and anatomy)

Conditions: Retinal Detachment

Summary: patients with retinal detachment do not always recover good visual function. sometimes simple causes are responsible. other causes can only be discovered thanks to high-resolution imaging provided by the latest generation of oct. this study is possible thanks to surgical teams who have a strong recruitment potential, with the experience of a joint project in 2007-2008 (phrc national - etude doremy, etude friends) to define more strict intervention criteria. the principal objective of this study is to better define with regard to time: * the onset of surgically curable or transient macular affections, and losses in visual acuity that can be qualified as "explained" * but above all to better understand the relationships between anatomical analyses obtained using oct and autofluorescence and functional analysis using visual acuity and microperimetry. * in the near future, two techniques (oct and microperimetry) will certainly become essential tools in the evaluation of macular function. better understanding of these relationships is the first necessary step in any study concerning the therapeutic prevention of retinal lesions related to retinal detachment: this study will make it possible to define criteria for the evaluation of anatomical and functional recovery, their relationship with each other and finally their evolution over time. this is an essential first phase before possible therapies can be evaluated.


Eligibility criteria:
inclusion criteria: * patients who have provided written informed consent * retinal detachment with pre-operative raised macula, re-attached during a surgical intervention with one month of follow-up * patients undergoing surgery as the first-line treatment (ab extern surgery or gas vitrectomy) * patients who accept to be followed for at least 12 months at the investigating center. exclusion criteria: * persons who are not registered with social security agency * macular affections pre-existent to the dr * retinal detachment requiring several interventions to obtain a reapplication * lazy eye with pre-operative * brightness of the circles not allowing the realization of the examinations
modifying group therapy for bipolar substance abusers - 1

Conditions: Bipolar Disorder; Substance Dependence

Summary: the purpose of this study is to modify integrated group therapy (igt), which is has been found successful for patients with bipolar disorder (bd) and substance use disorder(sud), so that it can be more readily adopted by community drug abuse treatment programs. igt is being reduced from 20 to 12 sessions in this trial, and is being conducted by front-line drug counselors, to test its effectiveness in a more community-based setting. the training has been expanded so that counselors without much psychopathology training or cognitive behavioral therapy experience can conduct igt.

igt is being compared with 12 sessions of group drug counseling (gdc) in a randomized controlled trial, with a sample size of 60 subjects. gdc is the type of treatment one would likely receive in a community drug abuse treatment program, in that it focuses primarily in substance use, unlike igt, which focuses equally on sud and bd issues. patients are followed for a year after the end of the group therapy, to examine the long-term effects of the treatment, and also to examine the longer-term relationship of substance use and mood. patients in the trial must be taking a mood stabilizer to enter the study. any drug of abuse is accepted, and all subtypes of bd are accepted.

Eligibility criteria:
inclusion criteria: * bipolar disorder substance dependence taking a mood stabilizer exclusion criteria: * acute psychosis no substance use in past 60 days no prescribing doctor will not be in area for next 15 months lives too far away

Keywords: substance abuse
mitoq and ischemic conditioning to assess vascular health outcomes

Conditions: Stroke

Summary: stroke survivors have compromised vascular function which may contribute to secondary stroke risk, cardiovascular disease, and may limit their exercise tolerance. preliminary data shows a single bout of ischemic conditioning or oral ingestion of an over-the-counter antioxidant supplement called mitoq may improve vascular function and muscle activity in individuals post-stroke.


Eligibility criteria:
inclusion criteria: * 18 - 85 years of age * cortical or sub-cortical stroke ≥ 6 months ago with residual hemiparesis * able to give informed consent and follow 2-step command. * english speaking exclusion criteria: * unable to stand from chair without physical assistance from another person (able to use assistive device). * history of blood clots in the extremities or any condition in which compression of the thigh or transient ischemia is contraindicated (i.e., wounds in the leg). * chronic lasting symptoms (\> 6 months) of severe covid-19 (i.e., hospitalization) * history of head trauma or concussion within the past 6 months * comorbid neurological disorder * peripheral vascular disease * myocardial infarction or arrhythmia in the previous year * resting sbp ≥180 mmhg or dbp ≥ 100 mmhg * pregnant or breastfeeding. * other significant medical condition likely to influence study or jeopardize safety as assessed by the primary investigator

Keywords: ischemic conditioning blood flow microvascular health flow-mediated dilation antioxidant reactive oxygen species supplement
comparison between effect of adrenaline and without adrenaline in tumescent solutions on bleeding control of skin graft donor site.

Conditions: Bleeding Time

Summary: the purpose of this study is to appraise if various concentration of adrenaline containing tumescent has any significant role in bleeding at skin graft donor site bleeding through photographic assessment.

tumescent solutions will be prepared by adding 30cc of ringer's lactate and 10cc of lignocaine 2%, with 1cc of adrenaline of 1:200,000 (which will be prepared by adding 1cc of adrenaline of 1:1000 conc. with 200ml of normal saline marked as solution "a" and without adrenaline marked as solution "b" to form the two different tumescent solutions. both solutions with be topically applied in soaked gauzes for around 10 minutes. solution a will be applied over the anterior side of thigh while solution b will be applied over lateral side of thigh. tumescent solutions will be prepared around 10 minutes before applying. after 10 min split-thickness skin graft donor sites will be harvested with a dermatome adjusted on with a randomized setting to harvest a fixed depth of wound depth. after harvesting skin graft the donor site wound will be photographed. the apparent severity of bleeding will be scored on an ordinal scale from 0 to 5 (0=no bleeding/staining, 1=minimal bleeding/staining, 2=mild bleeding/staining, 3=moderate bleeding/staining, 4=moderately severe bleeding/staining, 5=severe bleeding/staining by two independent surgeons. at last photographs will be compared with pre-infiltration records in each side. skin graft donor and recipient site will be inspected on the 5th post-operative day

Eligibility criteria:
inclusion criteria: * age above 18 years * both genders * non hypertensive patients * hemoglobin levels more than 10 g/dl * platelet count above 150 x 10e9/l * wounds for more than 6 weeks exclusion criteria: * • hypertensive patients, * bleeding tendencies (disorder), * immune-compromised, * familial history of bleeding
a study of a new investigational medicinal product to treat patients with advanced or metastatic solid tumors

Conditions: Advanced or Metastatic Solid Tumors

Summary: w0101 combines a cytotoxic compound to a monoclonal antibody targeting a receptor commonly overexpressed in many cancers. the development of antibody-drug conjugates takes advantage of the specificity of the mab while augmenting its ability to produce a cytotoxic effect. the expected benefits of antibody-drug conjugation are enhancement of cytotoxicity in target cells and limiting toxicities of cytotoxic drugs in normal tissues.

this is a first in human study, multicenter, open label study divided into 2 parts: an initial dose escalation phase (i) followed by expansion cohort(s) phase (ii).

Eligibility criteria:
inclusion criteria: dose escalation phase (cohort a1 and a2) 1. male or female subjects age ≥ 18 years 2. subjects with histologically or cytologically confirmed advanced or metastatic solid tumors (excluding lymphoma) , unresponsive to standard treatment or for whom no standard treatment is available or appropriate 3. ecog performance status 0 or 1 4. adequate bone marrow, renal, hepatic at screening and at baseline 5. subject must have measurable diseases as per recist v1.1 criteria exclusion criteria: 1. symptomatic brain metastases, cns tumors 2. symptomatic motor or sensory peripheral neuropathy (≥ grade 2) 3. subjects having ophthalmologic abnormalities 4. active serious systemic disease (infection,organic or dysmetabolic desease) 5. left ventricular ejection fraction (lvef) \< 45% as determined by muga scan or echography at screening 6. qtc \> 470 msec on screening ecg or congenital long qt syndrome 7. biologic therapy (including adcs ≤ 4 weeks before first study treatment administration)
skills of home helpers for a better quality of life for adults with huntington's disease living at home

Conditions: Quality of Life

Summary: huntington's disease often brings together 3 types of symptoms at one time or another of the disease during its evolution: motor, cognitive and psychiatric. management requires comprehensive and multidisciplinary health, social or medico-social support. its development generates additional difficulties for professionals who very often qualify this disease as "very complex" because it leads to a deep and severe impairment of physical and intellectual capacities. the sick person gradually loses their autonomy and becomes dependent for the acts of daily life, hence the choice of this disease for our study. our study is focused on the quality of life at home of patients followed by the angers reference center, "expert" on neurogenetic pathologies. studies focusing on patients' quality of life at home have so far never been undertaken for a rare neurodegenerative disease like huntington's disease.


Eligibility criteria:
selection criteria: patient group : * genetic diagnosis of huntington's disease * symptomatic patient * patient living at home * person able to carry out the interviews provided for in the study caregiver group : * person, defined within the meaning of the cnsa (national solidarity fund for autonomy) as a natural caregiver, not concerned himself by the risk of developing the disease * person able to carry out the interviews provided for in the study home helper group : - professionals working at home with huntington's disease patients employed by home help service providers.
immune damage and vaccination in copd patients

Conditions: Chronic Obstructive Pulmonary Disease

Summary: better understanding of the specificities of the vaccine response in patients with copd

chronic obstructive pulmonary disease (copd) will become the third leading cause of death worldwide in 2020 (3.5 million patients, 16500 deaths in france). its socio-economic cost is related to the handicap induced by the decline of the respiratory function, as well as to the occurrence of exacerbations, main causes of hospitalization and mortality. since exacerbations are mostly infectious, a preventive strategy involves routine influenza vaccination. although it is highly recommended in this population, there is no formal evidence of its effectiveness during copd. while correlates of influenza vaccine efficacy exist, cellular and humoral responses to this vaccine have been poorly evaluated in these patients. this alteration of the vaccine response could also be integrated into an overall deficit of the response to a vaccine in these patients. as influenza virus infection is one of the most important causes of death in patients with copd, and vaccination is the best way to prevent it, it is essential to better understand the immune response in the context of vaccination in this population. the investigator's hypothesis is that there would be a global alteration of the immunological immune response in the copd patient involving abnormalities of lymphocyte b differentiation and the effector capacity of t lymphocytes, notably through the activation of the pd1 / pdl1 axis.

Eligibility criteria:
inclusion criteria: * acceptance to participate in the protocol * affiliated to a social security scheme * age between 40 and 65 years copd patients * diagnosis of moderate to very severe copd with fev1 / fvc \<0.7 and fev1 \<80% of predicted value, cumulative smoking greater than 10pa * indication reminder dtp pertussis when the last booster \<5 years patients without copd * fev / fvc\> 0.8 * indication reminder dtp pertussis when the last booster \<5 years * indication and patient's wish for an influenza vaccination exclusion criteria: * refusal to participate in the study * progressive cancer and / or treated in the last 5 years, uncontrolled heart failure, connective tissue disease, inflammatory disease of the digestive tract during treatment. * exacerbation or any upper or lower respiratory infection in the previous month. * any cause of immunodepression, including long-term oral corticosteroids. * pregnant or lactating woman
effects of modified otago exercises in individuals with diabetic neuropathy

Conditions: Diabetes Mellitus, Type 2; Neuropathy

Summary: the aim of the study is to investigate the effects of modified otago exercises on joint position sense, balance and physical fitness parameters in individuals with diabetic neuropathy. in addition aim of to examine the effects of exercise on metabolic variables and to gain exercise awareness in diabetic individuals.


Eligibility criteria:
inclusion criteria: * individuals with neuropathy diagnosed with type 2 diabetes between the ages of 40-65 years * cooperative, able to take instructions (mini mental test score of 24 and above) * able to walk independently * with a body mass index below 40 kg/m2 * not doing regular physical activity for the last 6 months * voluntarily participated in the research exclusion criteria: * additional neurological problem other than neuropathy * any orthopedic or systemic problems that will prevent him from performing the exercises * the presence of pathology related to the lower limb that occurred within the last 6 months (surgery, fracture, soft tissue injuries, etc.) * pregnant * vision problem that cannot be corrected with glasses or lenses * hearing loss that cannot be corrected with hearing aids * foot ulcer * patients who have been diagnosed with cancer and are receiving chemotherapy in this context * with limitation of the range of motion of the joints of the lower extremities

Keywords: otago exercise joint position sense balance physical fitness
a study assessing the efficacy and safety of de-127 ophthalmic solution in subjects with mild or moderate myopia (apple)

Conditions: Myopia

Summary: to investigate the safety and efficacy of three concentrations of de-127 ophthalmic solution when compared to placebo in subjects diagnosed with mild or moderate myopia. to investigate the dose response of de-127.


Eligibility criteria:
inclusion criteria: * refractive error of spherical equivalent -1.0 diopter to -6.0 diopter in both eyes * anisometropia of spherical equivalent less than or equal to 1.50 diopter in both eyes * distance vision correctable to logmar 0.2 or better in both eyes * normal intraocular pressure of not greater than 21 mmhg in both eyes * no allergy to atropine, cyclopentolate, proparacaine and benzalkonium chloride exclusion criteria: * amblyopia or manifest strabismus including intermittent tropia * ocular disorders that potentially affect myopia or refractive power * previous or current use of contact lenses, bifocal lenses, progressive addition lenses, or other forms of treatment (including atropine and pirenzepine) for myopia * systemic disorders that potentially affect myopia or refractive power
combination chemotherapy in treating children with acute lymphoblastic leukemia, osteosarcoma, or non-hodgkin's lymphoma

Conditions: Leukemia; Lymphoma; Sarcoma

Summary: rationale: drugs used in chemotherapy, such as trimetrexate glucuronate and leucovorin, use different ways to stop cancer cells from dividing so they stop growing or die. combining more than one drug may kill more cancer cells. purpose: this phase ii trial is studying how well combination chemotherapy works in treating children with recurrent acute lymphoblastic leukemia, recurrent osteosarcoma, or refractory non-hodgkin's lymphoma.

objectives: * determine the efficacy of trimetrexate glucuronate with leucovorin calcium rescue in children with recurrent acute lymphoblastic leukemia, recurrent osteogenic sarcoma, or refractory non-hodgkin's lymphoma resistant to methotrexate. * evaluate the toxicity of this treatment regimen in this patient population. outline: patients are stratified according to disease (acute lymphocytic leukemia, non-hodgkin's lymphoma vs osteogenic sarcoma). patients receive trimetrexate glucuronate orally or iv every 12 hours on days 1-21 and oral leucovorin calcium every 12 hours on days 1-24. treatment repeats every 4 weeks. patients with stable or responsive disease may receive up to 4 courses of therapy. projected accrual: a total of 25 patients will be accrued for this study within 2 years.

Eligibility criteria:
disease characteristics: * histologic evidence of one of the following malignancies that has failed conventional therapy: * acute lymphoblastic leukemia * non-hodgkin's lymphoma with bone marrow involvement * osteogenic sarcoma * in vitro transport resistance to methotrexate demonstrated by bone marrow aspirate assay patient characteristics: age: * 21 and under at diagnosis performance status: * ecog 0-2 life expectancy: * at least 8 weeks hematopoietic: * granulocytopenia allowed with bone marrow involvement * thrombocytopenia allowed with bone marrow involvement * anemia allowed with bone marrow involvement hepatic: * (unless due to disease) * bilirubin no greater than 2.0 mg/dl * ast no greater than 100 renal: * creatinine less than 1.5 mg/dl or * creatinine clearance at least 60 ml/min other: * no other serious medical illness * not pregnant or nursing * fertile patients must use effective contraception prior concurrent therapy: biologic therapy: * prior bone marrow transplantation allowed chemotherapy: * at least 1 week since prior intrathecal treatment * at least 2 weeks since prior systemic chemotherapy and recovered * at least 10 days for rapidly proliferating leukemia (i.e., wbc greater than 50,000) * no concurrent chemotherapy endocrine therapy: * not specified radiotherapy: * prior radiotherapy allowed and recovered * no concurrent radiotherapy surgery: * not specified

Keywords: recurrent childhood acute lymphoblastic leukemia recurrent childhood lymphoblastic lymphoma recurrent osteosarcoma recurrent childhood small noncleaved cell lymphoma recurrent childhood large cell lymphoma
study to compare the efficacy and safety of pitavastatin and simvastatin

Conditions: Hypercholesterolemia; Dyslipidemia

Summary: the purpose of this study is to compare the efficacy and safety of pitavastatin with that of simvastatin in patients with risk factors for heart disease.


Eligibility criteria:
inclusion criteria: * males and females (18-75 years of age) * at least two cardiovascular disease risk factors * must have been following a restrictive diet * diagnosis of primary hypercholesterolemia or combined dyslipidemia exclusion criteria: * homozygous familial hypercholesterolemia * conditions which may cause secondary dyslipidemia * uncontrolled diabetes mellitus * abnormal pancreatic, liver or renal function * abnormal serum creatine kinase (ck) above the pre-specified level

Keywords: kowa kre hypercholesterolemia combined dyslipidemia dyslipidemia pitavastatin nk-104 simvastatin